Literature DB >> 10858224

Tumor necrosis factor alpha-mediated toxic shock in Trypanosoma cruzi-infected interleukin 10-deficient mice.

C Hölscher1, M Mohrs, W J Dai, G Köhler, B Ryffel, G A Schaub, H Mossmann, F Brombacher.   

Abstract

Using interleukin-10 (IL-10)-deficient (IL-10(-/-)) mice, previous studies revealed a pathological immune response after infection with Trypanosoma cruzi that is associated with CD4(+) T cells and overproduction of proinflammatory cytokines. In this study we further investigate the pathology and potential mediators for the mortality in infected animals. T. cruzi-infected IL-10(-/-) mice showed reduced parasitemia accompanied by increased systemic release of gamma interferon (IFN-gamma), IL-12, and reactive nitrogen intermediates and overproduction of tumor necrosis factor alpha (TNF-alpha). Despite this early resistance, IL-10(-/-) mice died within the third week of infection, whereas all control mice survived acute infection. The clinical manifestation with weight loss, hypothermia, hypoglycemia, hyperkalemia, and increased liver-derived enzymes in the blood together with hepatic necrosis and intravascular coagulation in moribund mice indicated a toxic shock-like syndrome, possibly mediated by the systemic TNF-alpha overproduction. Indeed, high production of systemic TNF-alpha significantly correlated with mortality, and moribund mice died with critically high TNF-alpha concentrations in the blood. Consequent treatment with anti-TNF-alpha antiserum attenuated pathological changes in T. cruzi-infected IL-10(-/-) mice and significantly prolonged survival; the mice died during the fourth week postinfection, again with a striking correlation between regaining high systemic TNF-alpha concentrations and the time of death. Since elevated serum IL-12 and IFN-gamma concentrations were not affected by the administration of antiserum, these studies suggest that TNF-alpha is the direct mediator of this toxic shock syndrome. In conclusion, induction of endogenous IL-10 during experimentally induced Chagas' disease seems to be crucial for counterregulating an overshooting proinflammatory cytokine response resulting in TNF-alpha-mediated toxic shock.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10858224      PMCID: PMC101698          DOI: 10.1128/IAI.68.7.4075-4083.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  Trypanosoma cruzi: IL-10, TNF, IFN-gamma, and IL-12 regulate innate and acquired immunity to infection.

Authors:  I A Abrahamsohn; R L Coffman
Journal:  Exp Parasitol       Date:  1996-11       Impact factor: 2.011

2.  The endogenous balance of soluble tumor necrosis factor receptors and tumor necrosis factor modulates cachexia and mortality in mice acutely infected with Trypanosoma cruzi.

Authors:  C Truyens; F Torrico; R Lucas; P De Baetselier; W A Buurman; Y Carlier
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

3.  V beta 6-bearing T cells are involved in resistance to Trypanosoma cruzi infection in XID mice.

Authors:  A Cordeiro da Silva; E C Lima; M H Vicentelli; P Minoprio
Journal:  Int Immunol       Date:  1996-08       Impact factor: 4.823

4.  Toxoplasma gondii triggers granulocyte-dependent cytokine-mediated lethal shock in D-galactosamine-sensitized mice.

Authors:  A J Marshall; E Y Denkers
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

5.  Murine IL-12 is involved in Calmette-Guérin bacillus-induced sensitization and is by itself sufficient to sensitize mice to the lethal effects of human TNF1.

Authors:  A Cauwels; W Fiers; P Brouckaert
Journal:  J Immunol       Date:  1996-06-15       Impact factor: 5.422

6.  Interleukin-10-deficient mice develop chronic enterocolitis.

Authors:  R Kühn; J Löhler; D Rennick; K Rajewsky; W Müller
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

7.  IL-10 mediates susceptibility to Trypanosoma cruzi infection.

Authors:  S G Reed; C E Brownell; D M Russo; J S Silva; K H Grabstein; P J Morrissey
Journal:  J Immunol       Date:  1994-10-01       Impact factor: 5.422

8.  Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia.

Authors:  C Gérard; C Bruyns; A Marchant; D Abramowicz; P Vandenabeele; A Delvaux; W Fiers; M Goldman; T Velu
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

9.  T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor.

Authors:  T Miethke; C Wahl; K Heeg; B Echtenacher; P H Krammer; H Wagner
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

10.  Macrophage deactivation by interleukin 10.

Authors:  C Bogdan; Y Vodovotz; C Nathan
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

View more
  68 in total

1.  Pivotal role of interleukin-12 and interferon-gamma axis in controlling tissue parasitism and inflammation in the heart and central nervous system during Trypanosoma cruzi infection.

Authors:  V Michailowsky; N M Silva; C D Rocha; L Q Vieira; J Lannes-Vieira; R T Gazzinelli
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

2.  B-cell-deficient mice show an exacerbated inflammatory response in a model of Chlamydophila abortus infection.

Authors:  Antonio J Buendía; Laura Del Río; Nieves Ortega; Joaquín Sánchez; María C Gallego; María R Caro; Jose A Navarro; Francisco Cuello; Jesús Salinas
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

3.  A network map of Interleukin-10 signaling pathway.

Authors:  Renu Verma; Lavanya Balakrishnan; Kusum Sharma; Aafaque Ahmad Khan; Jayshree Advani; Harsha Gowda; Srikanth Prasad Tripathy; Mrutyunjay Suar; Akhilesh Pandey; Sheetal Gandotra; T S Keshava Prasad; Subramanian Shankar
Journal:  J Cell Commun Signal       Date:  2015-08-08       Impact factor: 5.782

Review 4.  Adipocyte, adipose tissue, and infectious disease.

Authors:  Mahalia S Desruisseaux; Maria E Trujillo; Herbert B Tanowitz; Philipp E Scherer
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

Review 5.  Decomposing health: tolerance and resistance to parasites in animals.

Authors:  Lars Råberg; Andrea L Graham; Andrew F Read
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2009-01-12       Impact factor: 6.237

6.  Interleukin-17 mediated immunity during infections with Trypanosoma cruzi and other protozoans.

Authors:  María Carolina Amezcua Vesely; Constanza Rodríguez; Adriana Gruppi; Eva Virginia Acosta Rodríguez
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-01-24       Impact factor: 5.187

7.  Autocrine IL-10 induces hallmarks of alternative activation in macrophages and suppresses antituberculosis effector mechanisms without compromising T cell immunity.

Authors:  Tanja Schreiber; Stefan Ehlers; Lisa Heitmann; Alexandra Rausch; Jörg Mages; Peter J Murray; Roland Lang; Christoph Hölscher
Journal:  J Immunol       Date:  2009-06-26       Impact factor: 5.422

8.  Alterations in glucose homeostasis in a murine model of Chagas disease.

Authors:  Fnu Nagajyothi; Regina Kuliawat; Christine M Kusminski; Fabiana S Machado; Mahalia S Desruisseaux; Dazhi Zhao; Gary J Schwartz; Huan Huang; Chris Albanese; Michael P Lisanti; Rajat Singh; Feng Li; Louis M Weiss; Stephen M Factor; Jeffrey E Pessin; Philipp E Scherer; Herbert B Tanowitz
Journal:  Am J Pathol       Date:  2013-01-12       Impact factor: 4.307

Review 9.  The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseases.

Authors:  Christoph Hölscher
Journal:  Med Microbiol Immunol       Date:  2003-06-27       Impact factor: 3.402

10.  Short treatment with the tumour necrosis factor-alpha blocker infliximab diminishes chronic chagasic myocarditis in rats without evidence of Trypanosoma cruzi reactivation.

Authors:  A R Pérez; G H Fontanella; A L Nocito; S Revelli; O A Bottasso
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.